--- title: "AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update" type: "News" locale: "en" url: "https://longbridge.com/en/news/228568137.md" description: "AlloVir, Inc. (NASDAQ:ALVR) experienced a significant decrease in short interest in January, with totals dropping from 69,200 shares to 59,500 shares, a 14.0% decline. The short-interest ratio is currently 2.3 days, with approximately 2.6% of shares sold short. Hedge funds hold 66.05% of the stock, with notable increases in stakes from Northern Trust Corp and Jane Street Group LLC. AlloVir's stock opened at $9.90, with a market cap of $49.80 million and a 52-week range of $7.96 to $24.15." datetime: "2025-02-17T13:56:35.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/228568137.md) - [en](https://longbridge.com/en/news/228568137.md) - [zh-HK](https://longbridge.com/zh-HK/news/228568137.md) generator: "portal-rs" --- # AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update AlloVir, Inc. (NASDAQ:ALVR - Get Free Report) was the target of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 59,500 shares, a decrease of 14.0% from the January 15th total of 69,200 shares. Approximately 2.6% of the company's shares are sold short. Based on an average daily trading volume, of 26,100 shares, the short-interest ratio is currently 2.3 days. ## Hedge Funds Weigh In On AlloVir - MarketBeat Week in Review – 7/10 - 7/14 Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northern Trust Corp lifted its position in shares of AlloVir by 0.8% during the fourth quarter. Northern Trust Corp now owns 159,685 shares of the company's stock worth $67,000 after purchasing an additional 1,267 shares during the last quarter. Jane Street Group LLC raised its stake in AlloVir by 47.8% during the fourth quarter. Jane Street Group LLC now owns 123,159 shares of the company's stock worth $52,000 after acquiring an additional 39,808 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of AlloVir in the fourth quarter valued at approximately $25,000. Finally, Gilead Sciences Inc. acquired a new stake in shares of AlloVir in the fourth quarter valued at approximately $6,987,000. 66.05% of the stock is owned by hedge funds and other institutional investors. ## AlloVir Stock Up 0.2 % ALVR stock opened at $9.90 on Friday. The company has a market cap of $49.80 million, a price-to-earnings ratio of -0.49 and a beta of 0.65. The business has a fifty day simple moving average of $10.10 and a 200-day simple moving average of $14.58. AlloVir has a 52 week low of $7.96 and a 52 week high of $24.15. ## About AlloVir (Get Free Report) - Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus AlloVir, Inc engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. ## Further Reading - Five stocks we like better than AlloVir - What Investors Need to Know to Beat the Market - Symbotic Shares Down 37%—Is It Time for Bravery or Caution? - What is a Secondary Public Offering? What Investors Need to Know - High-Yield Healthcare: 3 Stocks With Strong Dividends - What Does a Stock Split Mean? - Beyond the Bargain Bin: 3 Stocks Leading Discount Retail *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Where Should You Invest $1,000 Right Now? Before you make your next trade, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now... See The Five Stocks Here ## Should You Invest $1,000 in AlloVir Right Now? Before you consider AlloVir, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AlloVir wasn't on the list. While AlloVir currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ALVR.US](https://longbridge.com/en/quote/ALVR.US.md) - [KLRS.US](https://longbridge.com/en/quote/KLRS.US.md) - [EPRT.US](https://longbridge.com/en/quote/EPRT.US.md) - [NTRS.US](https://longbridge.com/en/quote/NTRS.US.md) ## Related News & Research - [Kalaris Therapeutics management to join Morgan Stanley Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297513633.md) - [Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results](https://longbridge.com/en/news/295542706.md) - [Kalaris Therapeutics Q2 net loss narrows on lower administrative costs](https://longbridge.com/en/news/295534891.md) - [Kalaris Therapeutics director Laurie Keating files initial beneficial ownership statement](https://longbridge.com/en/news/294731013.md) - [Kalaris Therapeutics says TH103 Phase 1b/2 trial in neovascular AMD is enrolling patients](https://longbridge.com/en/news/290559679.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**